Background and Aims: The association between thiopurines and colorectal neoplasia risk remains controversial in inflammatory bowel disease [IBD] patients. We performed a systematic review and meta-analysis examining this association. Methods: A comprehensive search of the PubMed, EMBASE and Cochrane Library databases was performed to identify relevant literature. Random-effects models were applied to calculate the pooled odds ratio [OR] Conclusions: This study demonstrated that thiopurine use was associated with a reduced risk of colorectal neoplasia, advanced neoplasia and CRC in IBD patients, especially those with long disease duration [> 8 years].
Introduction

Inflammatory bowel disease [IBD], including ulcerative colitis [UC]
and Crohn's disease [CD] , is a type of chronic and relapsing intestinal inflammation with some extraintestinal complications. 1 The incidence and prevalence of IBD are increasing and several million individuals are suffering from IBD globally. 2, 3 In Europe, the EC-IBD study found that total incidence rates in northern Europe was 6.3 for CD and 11.4 for UC per 100 000 person-years, while in southern Europe they were for 3.6 and 8.0 per 100 000 person-years, respectively. 4 Colorectal cancer [CRC] is the most frequent malignant complication in patients with IBD. 5 Previous studies have reported that the incidence rates for the development of CRC in UC patients was 1.6% by 10 years, 8.3% by 20 years and 18.4% by 30 years after diagnosis 6 ; and CD increased the risk of CRC 4.5-fold compared with the general population. 7 It is well recognized that chronic inflammation is one of the most important risk factors for the development of CRC in patients with IBD. 8, 9 Therefore, a reduction in inflammation is supposed to reduce the risk of developing colorectal neoplasia. Certain drugs that are used to suppress inflammation, such as 5-aminosalicylates , 10 have been demonstrated to prevent the development of colorectal neoplasia.
The thiopurines, azathioprine [AZA] and 6-mercaptopurine , have been used for both long-term and maintenance treatment of 5-ASA-and/or glucocorticoid-dependent or refractory IBD for more than 20 years. 11 The EpiCom cohort, a prospective population-based cohort of IBD patients from 31 European centres covering a background population of 10.1 million, demonstrated that more than half of CD patients and one of five UC patients were treated with thiopurines. 12 Due to their non-specific anti-inflammatory properties, there has been an increased interest in the detection of the chemopreventive potential of thiopurines. However, thiopurines also increase the risk of malignancies by a variety of mechanisms including direct alterations in DNA, activation of oncogenes, reduction in immunosurveillance of malignant cells and impaired control of oncogenic viruses. [13] [14] [15] Many clinical and experimental trials [16] [17] [18] [19] [20] [21] have been devoted to exploring the effect of thiopurines on the risk of colorectal neoplasia in IBD patients and have presented a considerable variety in risk estimates, which has led to an ongoing debate concerning the potential chemopreventive effect of thiopurines in IBD. The results from two previous meta-analyses are also conflicting; one found a negative association, 22 while the other suggested a chemopreventive effect of thiopurines for colorectal neoplasia but not for advanced colorectal neoplasia [high-grade dysplasia and cancer] and CRC. 23 Therefore, we decided to perform a systematic review and metaanalysis of observational studies to evaluate the effect of thiopurines on the risk of developing colorectal neoplasia in IBD patients. Furthermore, we performed a meta-analysis to examine the effects of these compounds in specific subgroups of IBD patients at a particularly high risk for colorectal neoplasia, such as those with long disease duration, 24, 25 an extensive degree of colitis 26 Library databases up to May 2017 to identify studies that assess the impact of thiopurine use on the risk of IBD-associated colorectal neoplasia, without restrictions on language, year of publication or publication type. We also manually searched the reference lists of all initially selected articles, reviews and meta-analyses for other relevant studies. Unpublished studies were not searched. The following combination of medical subject headings [MeSH]/EMTREE terms or free text terms was used: azathioprine; 6-mercaptopurine; thiopurine; inflammatory bowel disease; colitis, ulcerative; crohn disease; colorectal; colon; rectum; neoplasms; cancer; adenoma; and tumor. Supplementary Table S2 provides details of the full literature search strategies.
Inclusion and exclusion criteria
First, we excluded irrelevant studies by screening the title and abstract of each of these articles. Then, according to the inclusion and exclusion criteria, we retrieved potentially eligible studies by reviewing the full text of all selected articles. Studies included in this metaanalysis must meet the following criteria: [1] cohort or case-control study of patients diagnosed with IBD; [2] evaluated and clearly defined the exposure of IBD patients to thiopurines; [3] reported colorectal neoplasia as predetermined endpoint; and [4] reported relative risks, odds ratio or hazard risk or provided data for calculations. Studies from which it was not possible to retrieve outcome data were excluded. Furthermore, case reports, case series, reviews, letters, comments and conference abstracts were also excluded. Two investigators [GYG and XMC] independently selected and identified eligible studies. Any discrepancies were resolved by discussion or by the senior author [LC].
Data extraction and quality assessment
Data were extracted independently by two investigators [HLH and WMX] , and discrepancies were assessed by a third investigator [CYL] to achieve a consensus. The following data were collected from all eligible studies: first author's name, year of publication, country, type of study design, distribution of IBD diagnosis, duration of disease, categories of thiopurines, treatment duration, outcomes, risk estimates with or without adjustment for potential confounders, and potential cofounders used for adjustment. The study quality was assessed according to the Newcastle-Ottawa scale, 30 and studies that received an ultimate score of seven or more stars were considered to be of high quality.
Statistical analysis
Odds ratios [ORs] and relative risks [RRs] with corresponding 95% confidence intervals [CIs] were considered for the effect size of association across case-control and cohort studies, respectively. The Cochran Q test and I 2 statistic were used to assess heterogeneity among studies. 31 For the Cochran Q test, the statistical significance level was 0.1; for the I 2 statistic, a value less than 50% suggested evidence of heterogeneity. 32 A random-effects model was applied for pooling the effect when the heterogeneity was significant, but otherwise, a fixed-effects model was applied.
Subgroup analyses were conducted according to the outcome, study population, treatment duration, sample size, follow-up, IBD type, location and adjustment for confounders. We compared the pooled RR or OR estimates from different subgroups with a test of interaction 33 and a p-value of < 0.05 for differences between subgroups was considered statistically significant. 34 Meta-regression analyses were also performed to identify possible sources of heterogeneity including study population, treatment duration, sample size, 
Results
Literature search
The initial search identified 1924 articles from the databases mentioned above and nine through manual searches. After the titles and abstracts were reviewed, 1577 articles were eliminated, as they were not relevant to the search topic. Of the remaining 91 studies, 63 were excluded according to the inclusion criteria of the present meta-analysis [Supplementary Table S3 ]. Five studies [37] [38] [39] [40] [41] were excluded because of unclear immunosuppressive therapy. Although we tried to connect with these authors to retrieve needed data, they could not provide useful information given the long interval involved. Among the excluded studies, three had been published as conference abstracts [42] [43] [44] and full-texts, 16, 21, 45 and thus full-text articles with more sufficient information were included and used in this meta-analysis. Through a personal communication with Dr. Ullman [May 12, 2017], we were assured that two American studies 46, 47 represented the same patient population. In an attempt to choose the most appropriate study for our analysis, we decided to include the study 46 that was more recent and that was based on a larger number of participants [418 46 vs 315 47 ]. Finally, we identified 27 studies, including 25 full-text articles and two conference abstracts, 48, 49 that examined the association between thiopurine use and the risk of development of colorectal neoplasia in IBD patients. The flow diagram of selection progression is shown in Figure 1. 
Study characteristics and quality assessment
The meta-analysis consisted of 11 cohort 16, 17, 46, 48, [50] [51] [52] [53] [54] [55] [56] Among the studies included, ten focused exclusively on UC patients, two focused extensively on CD patients, and 15 focused on both UC and CD patients. Sixteen studies were conducted in Europe, ten were in North America and one was in South Africa. Although two Dutch studies 52, 63 were both conducted using the PALGA database, according to a personal communication, they were confirmed to represent different patient populations. 22 Two separate studies, one a cohort study 16 and the other a nested case-control study, 21 included the CESAME observational cohort. Furthermore, Connel et al. 50 and Rutter et al. 59 conducted a study using the same database of St Mark's Hospital. However, the overlap period was short [3 years], and therefore both of them were included in the analysis. The results of the study quality assessment are shown in Supplementary Table S4 . For the included abstracts, 48, 49 we were unable to obtain sufficient information to assess the quality of this study due to the limitation of the abstract. All but four studies were awarded seven or more stars, which indicates high study quality. Figure 2 ].
Subgroup analyses
Due to the significant heterogeneity among the included studies, subgroup analyses were conducted to explore potential sources of heterogeneity. The details of the pooled ORs are summarized in Figure 3 . Eleven studies 18, 19, 21, [59] [60] [61] [62] [63] [64] [65] [66] used advanced neoplasia [high-grade dysplasia and CRC] as the outcome, which yielded a pooled OR of 0.51 [95% CI: 0.31-0.84]. In addition, a protective effect of thiopurines on the risk of CRC was also observed in ten studies 18, 19, 21, [59] [60] [61] [62] [63] 65, 66 that assessed the association between thiopurines and CRC [OR = 0.56, 95% CI: 0.34-0.93]. However, considerable heterogeneity still exists among these studies.
Four studies 18, 21, 61, 66 were regarded as population-based, while the remaining 12 studies were considered hospital-based Further subgroup analyses by whether studies had adjusted for confounders did not demonstrate significant heterogeneity between strata, although the association was always significant.
Sensitivity analyses
To assess whether any one study had a dominant effect on the results, one study was omitted in turn, and the remaining studies were analysed. The combined ORs of the incidence of colorectal neoplasia ranged from 0. 47 Figure S1 ], which suggests that the overall results were not sensitive to any single study. Furthermore, when only high-quality studies were considered, the association between thiopurine use and colorectal neoplasia remained significant [OR = 0.44, 95% CI: 0.29-0.66].
Meta-regression analysis
The results of meta-regression analyses indicated that study design [hospital-or population-based] may be potential sources of heterogeneity [p = 0.004], which was consistent with the results from subgroup analyses.
Publication bias
No evidence of asymmetry was observed in the funnel plots when they were inspected visually [Supplementary Figure S2] , and the p values for Begg's and Egger's tests for publication bias were 0.163 and 0.212, respectively. 
Incidence of colorectal neoplasia in the cohort studies
Subgroup analyses
A meta-analysis of data from ten studies 16, 17, 46, [50] [51] [52] [53] [54] [55] [56] that evaluated the association between thiopurines and advanced neoplasia revealed a chemopreventive effect against advanced neoplasia [RR = 0.96, 95% CI: 0.94-0.98]. Such a protective effect was also seen in eight studies 16, 17, 50, 51, [53] [54] [55] [56] that assessed the effect of thiopurines on the risk of CRC [RR = 0.96, 95% CI: 0.94-0.98] [ Figure 5 ]. Two populationbased studies 16, 55 resulted in an RR of 0.84 [95% CI: 0.54-1.32] among patients who were exposed to thiopurines. However, the protective effect of thiopurines was seen in the hospital-based studies. In terms of treatment duration, we found a significant reduction in colorectal neoplasia after > 6 months of treatment. When the studies were grouped according to the duration of follow-up, the analysis revealed a protective effect of thiopurines in studies with longer duration of follow-up [> 5 years], but no statistically significant effect in those with shorter duration of follow-up [< 5 years]. Moreover, in contrast to the small-sized group [< 100], the protective effect of thiopurines was demonstrated in the large-sized group [> 100].
Sensitivity analyses
With the exception of one study, 54 when single studies were excluded in turn, the pooled RRs for the above-mentioned associations did not change [Supplementary Figure S3 ]. In addition, the sensitivity analysis, which analysed ten high-quality studies, showed results that were consistent with the overall pooled results [RR = 0.96, 95% CI: 0.94-0.98].
Meta-regression analysis
In meta-regression analyses, we tested the effect of study population, treatment duration, sample size, IBD type, location and adjustment for confounders on the association between thiopurine use and the risk of colorectal neoplasia. However, no statistical significant was found.
Publication bias
Visual inspection of the funnel plot did not reveal asymmetry, as illustrated in Supplementary Figure S4 . In addition, Begg's and Egger's tests did not suggest significant evidence of publication bias [p = 0.640 and 0.353, respectively].
Effect of thiopurines on higher-risk IBD patients
Sixteen studies [five cohort 16, 46, 50, 54, 56 and 11 case-control studies [19] [20] [21] [57] [58] [59] [60] [62] [63] [64] 68 ] assessed the effect of thiopurines on patients with disease for at least 8 years. As shown in Table 2 , the chemopreventive effect was observed in both the cohort and the case-control studies of colorectal neoplasia, advanced neoplasia and CRC. Compared with patients with long disease duration, no significant protective role of thiopurines was shown in patients with short disease duration among case-control or cohort studies [ Figure 6 ]. However, this subgroup difference did not reach statistical significance. After using three cohort 16, 46, 50 and three case-control 57,59,60 studies to conduct meta-analyses as to the effect on patients with extensive colitis, a negative association was found for colorectal neoplasia, advanced neoplasia and CRC. Additionally, only one study 58 investigated the association between thiopurines and colorectal dysplasia in IBD patients with PSC. Due to the limited number of studies, the result was inconclusive.
Discussion
This systematic review and meta-analysis was conducted to test the hypothesis that thiopurines might exert a protective effect against the risk of colorectal neoplasia in patients with IBD. We synthesized evidence from 27 studies that reported the association between thiopurines and colorectal neoplasia in IBD patients.
Principal findings
Overall, our results suggested a protective effect of thiopurines against colorectal neoplasia in both case-control and cohort studies. Furthermore, in the subgroup analyses, we found that the use of thiopurines was associated with a reduced risk of developing advanced neoplasia and CRC. The robustness of the overall effect estimates in the sensitivity analyses reinforced our confidence in the validity of the results. Moreover, in an effort to detect publication bias, Begg's and Egger's tests did not demonstrate significance among the cohort or case-control studies.
Established risk factors for IBD-associated colorectal neoplasia are well recognized and include a disease duration of at least 8 years, 69 extensive colitis 24 and coexisting PSC. 70 To the best of our knowledge, this is the first meta-analysis to explore the effect of thiopurines on the risk of colorectal neoplasia in IBD patients with these high-risk factors. Regarding the long duration of disease [> 8 years], our study demonstrated that thiopurines exposure decreased the risk of colorectal neoplasia, advanced neoplasia and CRC. This effect was stronger than in the general population of IBD patients. This effect was also consistent with the hypothesis that thiopurines are chemopreventive due to their anti-inflammatory effects. For extensive colitis and coexisting PSC, after the limited number of studies were pooled together, no positive association was observed. More large-scale studies are warranted to investigate the effect of thiopurines on high-risk IBD patients.
It is interesting that the protective effect of thiopurines was observed in hospital-based studies, but not in population-based studies. In addition, the differences between the hospital-based and population-based studies in our analysis were attributed to heterogeneity. These novel findings could be explained as follows. The patients included in the hospital-based studies usually had more severe disease activity and had a higher risk for the development of colorectal neoplasia than those in the population-based studies. Moreover, compared with the patients in the community, the inpatients usually take medicine more regularly, and their confounders can be better NOTE: Weights are from random effects analysis Overall (I−squared = 65.2%, p = 0.000) Lashner (1997) Case-control Study Kirchgesner (2016) Carrat (2017) Nieminen (2014) Kopylov (2015) Armstrong (2010) Baars (2011) Lakatos (2006) Velayos (2006) Gordillo (2015) Rutter (2004) Rubin (2013) Navaneethan (2016) Tung (2001) Nowacki (2015) Tang ( recorded. Notably, only four population-based case-control studies and two population-based cohort studies were included. The small number of studies had limited statistical power. Therefore, the results from the population-based studies should be interpreted with caution.
In the analysis according to study design, the preventive effect of thiopurines was evident among the case-control studies but was weaker among the cohort studies, regardless of the outcome of colorectal neoplasia, advanced neoplasia or CRC. Surveillance bias could explain some of the differences between the cohort and case-control studies. During the follow-up period, the patients exposed to thiopurines would have been more likely to visit the hospital and be seen by physicians than those who were not exposed. As they would be aware of the association between IBD and colorectal neoplasia, physicians would be more likely to diagnose colorectal neoplasia and biopsy any suspicious colonic lesions in patients who were prescribed thiopurines than in those who were not prescribed thiopurines. This is the reason for the increased frequency of colorectal neoplasia in thiopurine-exposed patients among the cohort studies.
Limitations of this study
Several limitations of this systematic review and meta-analysis should be considered. First, as all included studies were observational, these studies lacked the experimental random allocation of intervention compared with randomized controlled trials and may suffer from selection and information bias. The results may have also been confounded by several factors. Furthermore, each of these studies adjusted for somewhat different potential confounders. Second, because of insurmountable obstacles such as ethical problems, prospective randomized controlled trials could not be performed. However, data on chemoprevention in IBD patients are not clearly definitive and refer to retrospective cohort and case-control studies. Consequently, large prospective studies that appropriately adjust for potential confounders are needed to confirm the effect of thiopurines. As the only prospective study in those included, that by Beaugerie et al. 16 consisted of a subgroup analysis of the CESAME database with 19 486 consecutive IBD patients and found that thiopurines exerted a chemopreventive effect against the risk of advanced neoplasia [HR = 0.28, 95% CI: 0.09-0.89] and CRC [HR = 0.26, 95% CI: 0.07-0.98] in patients with long-standing extensive colitis [> 10 years disease duration and > 50% of the colon affected] after adjustments for sex, IBD subtype, disease duration and age at diagnosis of advanced neoplasia. Third, all studies included in this meta-analysis differed in study design [cohort or case-control], follow-up duration and definition of exposure to thiopurines [current use, ever use, discontinued use, ongoing use, and use for > 4 months, > 6 months, > 1 year, > 2 years or > 3 years]. Therefore, moderate heterogeneity was observed among the studies, and it was difficult to perform dose-response analyses based on all the definitions of exposure. Nevertheless, through our subgroup analysis, we were able to identify the study population as one of the sources of heterogeneity. 
Comparison with other studies
Until now, only two meta-analyses have examined the association between thiopurine exposure and the risk of colorectal neoplasia. Based on 19 observational studies, Gong et al. 23 identified a chemopreventive effect against colorectal neoplasia, with an RR consistent with that observed by us. However, they failed to find a preventive effect in advanced neoplasia and CRC development. The other meta-analysis did not find a significant protective effect of thiopurines on the risk of colorectal neoplasia in IBD patients [OR: 0.87; 95% CI: 0.71-1.06]. 22 Different inclusion criteria may be the cause of the varying results. Among the only 15 included studies, two 39, 40 considered the use of immunomodulators, rather than the use of thiopurines, as exposure. There are many different immunodulators using in the treatment of IBD except thiopurines, such as methotrexate, cyclosporine, calcineurin inhibitors and tacrolimus. Furthermore, there were two studies 46, 47 represented the same patient population. We included one study that was more recent and was based on a larger number of participants. However, Jess et al. 22 included both of the studies in their analysis, which must have an influence on the results in their study. Moreover, in a comparision with the previous meta-analyses, we analysed the results separately by study type, which provided stronger evidence of a protective effect of thiopurines among IBD patients.
Possible explanations and policy implications
Except for their anti-inflammatory properties, some other possible mechanisms underlie the chemopreventive effect of thiopurines. In a murine colitis-associated colorectal cancer model, thioguanine, a relatively fast-acting thiopurine, was demonstrated to exert a chemopreventive effect against the incidence of dysplasia independent of any anti-inflammatory action. 71 In addition, some studies demonstrated a mucosal healing effect of thiopurines at a rate as high as 69%, especially in corticosteroid-dependent patients. 72, 73 Growing evidence has shown that mucosal healing is associated with a reduced risk of colorectal neoplasia. 74, 75 Furthermore, the interaction among redox homeostasis, apoptosis and autophagy has been identified to mediate the chemopreventive effects of thiopurines. 76 Consistent with these mechanisms, our results add to the body of evidence that supports the chemopreventive effect of thiopurines against colorectal neoplasia in IBD patients. The ECCO-EpiCom study has previously documented the wide use of immunomodulators and currently an earlier and more frequent use of immunomodulating therapy. [77] [78] [79] Moreover, this disease impacted every aspect of the affected individual's life and account for substantial cost to the healthcare system and society. In the ECCO-EpiCom cohort, the mean crude expenditure per patient was €21 695 for CD and €26 180 for UC in Western Europe and €25 264 and €14 783, in Eastern Europe, respectively. 80 The findings in our study have considerable importance with respect to clinical and health policy because thiopurines are inexpensive and may provide a cost-effective approach to reduce the risk of colorectal neoplasia in IBD patients. Although thiopurines are associated with an increased risk of lymphoma 81, 82 and non-melanoma skin cancer, 51, 83 the absolute rates of these malignancies remain low, and the benefits of thiopurines outweigh the risk of malignancies according to the newest ECCO guideline. 84, 85 If finally proven to be chemopreventive, thiopurines might represent a new strategy to assist clinicians in the management of the risk for colorectal neoplasia in IBD patients. Fraser (2002) Satchi (2013) Camus (2013) Garcia (2013) Beaugerie (2013) Gupta ( 
Insight for future research
In the last two decades, the management of IBD has evolved greatly, spurred on by the growing use of immunomodulators [especially thiopurines] and the use of biological drugs, such as anti-tumor necrosis factor-α agents [anti-TNFα therapy]. 77 Combination therapy with thiopurines and anti-TNFα agents has emerged as the most effective option to induce and maintain remission in the majority of patients with moderate to severe disease. 86, 87 The pharmacodynamic interactions between thiopurines and anti-TNFα agents have greatly reduced immunogenicity and increased drug levels of biologics. However, it is not known if the combination therapy has a protective effect against colorectal neoplasia in IBD patients. Unfortunately, due to the limited number of studies, we did not perform a metaanalysis on the impact of combination therapy on the risk of colorectal neoplasia. Among our included studies, only one 66 investigated the association between combination therapy and the risk of CRC [RR = 1.06, 95% CI: 0.46-2.41]. Future studies are necessary to clarify this aspect and provide more precise estimates of the impact of combination therapy on colorectal neoplasia risk in IBD patients.
Conclusion
Our results demonstrate that thiopurines have a protective effect against colorectal neoplasia, advanced neoplasia and CRC, especially in patients with long duration of disease [> 8 years]. Before recommendations can be made, large prospective studies that adjust for potential confounders are warranted to confirm these findings and to enable a better understanding of the role of thiopurines for the prevention of colorectal neoplasia. 
